Clinical trials: Stroke Recurrence, open to volunteers
Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic
Left Atrial Strain and Cryptogenic Stroke
Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke.
- Conditions
- Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Hemorrhagic Stroke, Embolic Stroke of Undetermined Source
- Trial name
- LAS-ESUS (NCT07224178)
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of Pittsburgh
Stroke, Ischemic
Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial
The overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to…
- Trial name
- STROKE75+ (NCT07454707)
- Testing
- Edoxaban 15 mg, Aspirin or clopidogrel
- Where
- Canada
- Volunteers
- 1,204 people
- Sponsor
- Sunnybrook Health Sciences Centre
Stroke
Reduction of Recurrence of Stroke by Nurse-led Education in Bangladesh
Stroke is a major public issue that can be occurred a patient with severe and unbearable disability for a long time. Recurrence of stroke is increasing due to a lack of knowledge and compliance with treatment regarding the…
- Trial name
- NCT05520034
- Testing
- Health Education
- Where
- Bangladesh
- Volunteers
- 432 people
- Sponsor
- Hiroshima University
Stroke (CVA) or TIA, Stroke Recurrence
NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks
In this project, we aim to validate a Home Hospitalization plan for patients with TIA or minor stroke. Our hypothesis is that our Multimodal Home Hospitalization program (NORAHOME) for patients with TIA and minor stroke is safe…
- Trial name
- NORAHOME (NCT07500116)
- Testing
- Home hospitalization
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Ischemic Stroke, Intracranial Atherosclerosis
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for…
- Trial name
- CATIS-ICAS (NCT07468448)
- Testing
- Rivaroxaban, ASA
- Volunteers
- 1,172 people
- Sponsor
- Population Health Research Institute
Ischemic Stroke, Acute
A Multicenter Study Based on Multi-omics Analysis to Predict the Early Prognosis and Recurrence Risk of Acute Ischemic Stroke
Through a multicenter prospective AIS cohort study, we analyze the potential association of human proteome, microbiome and metabolome alterations with AIS prognosis, searching for key proteins, differential organisms and…
- Trial name
- NCT06584565
- Testing
- microbiome; metabolomics; proteomics
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Ischemic Stroke
Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage
The aim of this study is to investigate the association between intraplaque hemorrhage (IPH) detected by non-contrast magnetic resonance imaging (MRI) of the carotid artery in routine clinical practice and ipsilateral acute…
- Trial name
- PARADE (NCT06749106)
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Stroke, PFO - Patent Foramen Ovale
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a…
- Trial name
- REDUCE PAS (NCT03821129)
- Testing
- PFO closure with GORE® CARDIOFORM Septal Occluder
- Where
- 45 sites in United States
- Volunteers
- 636 people
- Sponsor
- W.L.Gore & Associates
Brain Diseases, Ischemic Stroke
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in…
- Conditions
- Brain Diseases, Ischemic Stroke, Ischemia, Stroke
- Trial name
- IRIS-sICAS (NCT06447701)
- Testing
- Tocilizumab, NaCl 0.9% 100ml
- Volunteers
- 486 people
- Sponsor
- Zhujiang Hospital
Stroke
CiLostAzol for pReventIon of Recurrent sTroke in Africa
Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke.
- Trial name
- CLARITY-Africa (NCT06919835)
- Testing
- Cilostazol 100 mg
- Where
- Ghana
- Volunteers
- 1,100 people
- Sponsor
- Northern California Institute of Research and Education
Ischemic Cerebral Infarction
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by…
- Trial name
- ORIS (NCT07242599)
- Testing
- High target group, Low target group
- Where
- 199 sites in China
- Volunteers
- 4,810 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke
Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting
This study aims to evaluate the clinical significance of clopidogrel resistance-associated biomarkers (TMAO, C1q, and C4BPα) in patients receiving cerebral artery stents, and to develop an integrated predictive model…
- Trial name
- NCT07028775
- Where
- China
- Volunteers
- 839 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Cervical Artery Dissection, Pregnancy Complications
Risk of Recurrent CeAD After Pregnancy
Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.
- Trial name
- LONG-RECAP (NCT06258109)
- Where
- 12 sites in United States, Argentina and 7 more
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Basel, Switzerland
Intracerebral Haemorrhage
Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage
BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75…
- Trial name
- BEAT-ICH (NCT07243704)
- Testing
- Aspirin 75 mg daily
- Where
- 33 sites in India
- Volunteers
- 5,676 people
- Sponsor
- Christian Medical College and Hospital, Ludhiana, India
Acute Ischemic Stroke
An Application Provides Temperature-related Health Risk Warnings and Protective Recommendations on Stroke
This study applied an application to provide early warnings and advice for stroke patients and explored the impact of this intervention on reducing the risk of stroke recurrence
- Trial name
- NCT07097428
- Testing
- Temperature health risk early warning
- Volunteers
- 5,092 people
- Sponsor
- Xuanwu Hospital, Beijing
Secondary Stroke
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications.
- Trial name
- ROXI-DAISEN (NCT07876492)
- Testing
- Cenvacibart
- Volunteers
- 6,106 people
- Sponsor
- Regeneron Pharmaceuticals
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Acute Ischemic Stroke
Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke
Through a single-center retrospective cohort study of acute ischemic stroke (AIS) patients receiving secondary prevention with indobufen, clopidogrel, cilostazol, or aspirin as monotherapy or dual therapy, we aim to compare the…
- Trial name
- NCT07604298
- Testing
- indubufen, aspirin, clopidogrel, cilostazol
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stroke
Stroke Homecare and Recurrence Prevention
Background and Significance: Stroke is the leading cause of death in China, placing a heavy burden on patients, families, and society.
- Trial name
- SHARP (NCT06810024)
- Testing
- Home-based therapy, Standard Care (in control arm)
- Volunteers
- 1,614 people
- Sponsor
- Peking Union Medical College
Ischemic Stroke, Atrial Fibrillation
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders, Brain Diseases
- Trial name
- CARE-AF (NCT06954610)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern